Rob Badman

Every week two experts from our share tips columnist pool give us their buy, hold and sell recommendations. 

The ASX 200 closed out hump day largely holding onto its early gains. Cooling local inflation data and a Wall Street lift helped matters.

The ASX lacks vigour on Monday after Friday's flat close on Wall Street. James Hardie and miners led losses in early trade. 

ASX traders and investors appear to be treading carefully on a Thursday in which global conflict headlines are still dominating. 

Good morning and welcome to Stockhead’s Top 10 at 11 – a short, sharp update to help frame the trading day.

This biotech's problem is that investors became jaded by the slow commercialisation and strategy whoopsies. There are signs of a turnaround.

Good morning, and welcome to Stockhead’s Top 10 at 11-ish, a short, sharp update to help frame the trading day.

Gold has ended the week in decent form, trending up about 0.11% French bank Société Générale may be nervy about oil, but it’s still feeling good about gold ASX goldie weekly winners include: ADG, AQI and PUA Gold is precious, and so is your time. Let’s get into it then, and get on to the weekend. Here’s the yellow metal’s news in brief, starting with some price action… Gold – the latest • The leading precious metal is in decent shape, changing hands for about US$2,368 pe…

The price of gold is clinging to crucial support levels as we close out a topsy-turvy week for precious metal commodities The World Gold Council is doing its best to prop up the gold market, though – particularly in Singapore ASX goldies making solid gains this week include: AGC, CDT, PRX Friday afternoon. Another weekend upon us. That’s gold. (And wet, if you’re in Sydney.) Let’s make this relatively brief as we cover off some of the relevant weekly news, take a quick look at t…

The Equador project is continuing to show its potential with first assay results returning partial rare earth oxides (PREO), niobium and tantalum Rock chip samples were collected directly from outcropping pegmatite intrusions Assays have been sent to another lab so that a full suite analysis can be contacted Special report: First assay results from the Equador project in Brazil have confirmed high-grade niobium and tantalum over a 1.2km strike length. Summit Minerals (ASX:SUM)…

Gold price consolidates as more inflation-influencing US economic data looms on Friday The World Gold Council sees positive narrative for gold remaining intact this year Top performing ASX goldies this week led by: SIH, CBY, KTA This week in gold. The Fed’s JPow spoke. Saw no sign of stag, no sign of ’flation. The precious yellow metal pulled back a tad. A mere bump in the road? Further golden days ahead, predict analysts. Let’s look a little closer, using slightly longer sente…

12-week Phase I/II clinical trial to treat Rett Syndrome with NTI164 broad spectrum cannabinoid drug therapy extended to 52 weeks All 14 female patients to receive NTI164 under care of Associate Professor Carolyn Ellaway Phase I/II 12 week data expected late Q1 to earl Q2 CY2024 The Rett Syndrome market is estimated at US$2 billion per annum Special Report: Health tech business Neurotech International has extended its Phase I/II clinical trial to explore the usage of its lead NT…

Heavy Minerals lifts off thanks to potential offtake garnet sales deal Macro Metals continues its climb from yesterday after prominent investors join board ADG, MKG and VMS also make the top ressie grade this morning with solid gains Here are some of the biggest resources winners in early trade, Thursday March 7. Heavy Minerals (ASX:HVY) Garnets. That’s what Heavy Minerals is largely into, at Port Gregory in WA… along with the Inhambane Mineral Sands project in Mozambique.…

PharmAust engages globally renowned experts in MND/ALS to form a scientific advisory board (SAB) The SAB will provide expert advice for the development of monepantel to treat MND/ALS The SAB will also support the planning stages for PharmAust’s adaptive Phase 2/3 clinical study Special Report: PharmAust has engaged globally renowned experts in MND/ALS and rare neurodegenerative diseases to form a scientific advisory board (SAB) for the next stage of development of monepantel (MPL)…

Australian Mines continues to advance its new Brazilian-focused strategy Initial work at the Resende lithium project confirms the potential to host same mineralisation as nearby Mibra mine Preliminary exploration has begun at Jequie, right next door to the monster 510Mt deposit owned by the Gina Rinehart-backed Brazilian Rare Earths Special Report: Australian Mines has made a positive start to exploration at the Resende lithium project it is looking to acquire as part of its Brazil…

LTR Pharma helped prop up a flaccid Aussie IPO scene in 2023 with a winning ROI Lithium Universe wasn’t far behind, leading battery metal newcomers As you may be aware, 2023 was a challenging year overall for IPO (Initial Public Offering) launches in Australia. In fact, that’s putting it lightly – in total, it was the worst capital-raising year for Aussie floats since 1995. And it was a reflection of the global IPO market landscape, which saw volumes falling by 8% and proceeds d…

EV sales slowdown narrative? Pfft, yeah right. Australia just hit record yearly EV sales and globally they're going strong, too.

Animoca Brands’ Mocaverse has pulled in another huge sum of funding from top investors, including Polygon Ventures and Dapper Labs This new round boosts the total capital raising for the project to US$31.88 million Special Report: Animoca Brands, a top Web3 firm focused on gaming, digital property rights and the open metaverse, has announced a further big raise for its highly anticipated Mocaverse project. In September, Animoca Brands completed a US$20 million raise for its Mocav…

With its innovative erectile dysfunction nasal spray treatment in advanced development, LTR Pharma is already creating serious buzz. Ahead of its ASX listing next week, the firm’s lead broker chatted with Stockhead. Affecting more than 60% of Aussie blokes over the age of 45 and set to deflate more than 322 million men globally by 2025, erectile dysfunction (ED) is a far more common issue than you might’ve ventured to think. LTR Pharma is very well across this and knows just how big a…

Lithium spot prices and many related mining/exploration stocks are trending lower right now. Was it something you said, Goldman Sachs?